Reinilde Heyrman

1.1k total citations
31 papers, 791 citations indexed

About

Reinilde Heyrman is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Nutrition and Dietetics. According to data from OpenAlex, Reinilde Heyrman has authored 31 papers receiving a total of 791 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Cardiology and Cardiovascular Medicine, 12 papers in Endocrinology, Diabetes and Metabolism and 9 papers in Nutrition and Dietetics. Recurrent topics in Reinilde Heyrman's work include Blood Pressure and Hypertension Studies (23 papers), Hormonal Regulation and Hypertension (11 papers) and Sodium Intake and Health (9 papers). Reinilde Heyrman is often cited by papers focused on Blood Pressure and Hypertension Studies (23 papers), Hormonal Regulation and Hypertension (11 papers) and Sodium Intake and Health (9 papers). Reinilde Heyrman collaborates with scholars based in United States, Germany and Belgium. Reinilde Heyrman's co-authors include Michael Melino, James Lee, Steven G. Chrysant, Suzanne Oparil, Víctor Fernández, James Lee, Joseph L. Izzo, Thomas Littlejohn, Dean J. Kereiakes and Subhas S. Karki and has published in prestigious journals such as Hypertension, The Journal of Urology and American Heart Journal.

In The Last Decade

Reinilde Heyrman

30 papers receiving 746 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Reinilde Heyrman United States	17	654	406	180	173	98	31	791
Joanne Holland United States	3	706 1.1×	289 0.7×	142 0.8×	177 1.0×	56 0.6×	4	803
Jackie Salsbury United Kingdom	6	637 1.0×	524 1.3×	171 0.9×	235 1.4×	57 0.6×	7	904
Lansheng Gong China	8	931 1.4×	313 0.8×	126 0.7×	189 1.1×	48 0.5×	10	1.1k
J NEUTEL United States	19	808 1.2×	329 0.8×	144 0.8×	126 0.7×	46 0.5×	61	1.0k
Lindon M.H. Wing Australia	15	1.3k 1.9×	380 0.9×	280 1.6×	276 1.6×	71 0.7×	26	1.6k
Walter A. Brzezinski United States	9	484 0.7×	244 0.6×	72 0.4×	214 1.2×	37 0.4×	16	748
Jan Otto Syvertsen Norway	5	649 1.0×	361 0.9×	83 0.5×	107 0.6×	71 0.7×	7	754
D García-Barreto Cuba	8	899 1.4×	402 1.0×	166 0.9×	148 0.9×	97 1.0×	30	1.0k
Eric Judd United States	14	884 1.4×	432 1.1×	289 1.6×	291 1.7×	36 0.4×	33	1.3k
Allan I. Goldberg United States	17	908 1.4×	526 1.3×	74 0.4×	90 0.5×	94 1.0×	20	1.1k

Countries citing papers authored by Reinilde Heyrman

Since Specialization

Citations

This map shows the geographic impact of Reinilde Heyrman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reinilde Heyrman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reinilde Heyrman more than expected).

Fields of papers citing papers by Reinilde Heyrman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reinilde Heyrman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reinilde Heyrman. The network helps show where Reinilde Heyrman may publish in the future.

Co-authorship network of co-authors of Reinilde Heyrman

This figure shows the co-authorship network connecting the top 25 collaborators of Reinilde Heyrman. A scholar is included among the top collaborators of Reinilde Heyrman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reinilde Heyrman. Reinilde Heyrman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Rao, Sunil V., Uwe Zeymer, Pamela S. Douglas, et al.. (2015). A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trial. American Heart Journal. 170(5). 929–937. 34 indexed citations

2.

Lewin, Andrew, et al.. (2013). Combined Olmesartan, Amlodipine, and Hydrochlorothiazide Therapy in Randomized Patients with Hypertension: A Subgroup Analysis of the TRINITY Study by Age. Drugs & Aging. 30(7). 549–560. 8 indexed citations

3.

Chrysant, Steven G., Thomas Littlejohn, Joseph L. Izzo, et al.. (2012). Triple-Combination Therapy with Olmesartan, Amlodipine, and Hydrochlorothiazide in Black and Non-Black Study Participants with Hypertension. American Journal of Cardiovascular Drugs. 12(4). 233–243. 18 indexed citations

4.

Kereiakes, Dean J., Steven G. Chrysant, Joseph L. Izzo, et al.. (2012). Long‐Term Efficacy and Safety of Triple‐Combination Therapy With Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide for Hypertension. Journal of Clinical Hypertension. 14(3). 149–157. 16 indexed citations

5.

Chrysant, Steven G., Thomas Littlejohn, Joseph L. Izzo, et al.. (2012). Triple-Combination Therapy with Olmesartan, Amlodipine, and Hydrochlorothiazide in Black and Non-Black Study Participants with Hypertension. American Journal of Cardiovascular Drugs. 12(4). 233–243. 16 indexed citations

6.

Wells, Thomas G., Douglas L. Blowey, Jeffrey L. Blumer, et al.. (2012). Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients with Hypertension. Pediatric Drugs. 14(6). 401–409. 8 indexed citations

7.

Kereiakes, Dean J., Steven G. Chrysant, Joseph L. Izzo, et al.. (2012). Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovascular Diabetology. 11(1). 134–134. 22 indexed citations

8.

Salazar, Daniel E., Jingpu Shi, Shashank Rohatagi, et al.. (2011). The Use of Modeling and Simulation to Guide Clinical Development of Olmesartan Medoxomil in Pediatric Subjects. Clinical Pharmacology & Therapeutics. 91(2). 250–256. 8 indexed citations

9.

Izzo, Joseph L., Steven G. Chrysant, Dean J. Kereiakes, et al.. (2011). 24-Hour Efficacy and Safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY Ambulatory Blood Pressure Substudy. Journal of Clinical Hypertension. 13(12). 873–880. 30 indexed citations

10.

Chrysant, Steven G., James Lee, Michael Melino, Subhas S. Karki, & Reinilde Heyrman. (2010). Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. Journal of Human Hypertension. 24(11). 730–738. 35 indexed citations

11.

Melino, Michael, et al.. (2010). 24-HOUR EFFICACY AND SAFETY OF FULL-DOSE, TRIPLE-COMBINATION THERAPY WITH OLMESARTAN, AMLODIPINE, AND HYDROCHLOROTHIAZIDE: THE TRINITY STUDY: PP.5.174. Journal of Hypertension. 28. e100–e100. 3 indexed citations

12.

Kereiakes, Dean J., et al.. (2010). EFFICACY AND SAFETY OF COMBINATION OLMESARTAN MEDOXOMIL (OM)+AMLODIPINE BESYLATE (AML)+HYDROCHLOROTHIAZIDE (HCTZ) BASED ON SEVERITY OF HYPERTENSION: THE TRINITY STUDY: PP.5.164. Journal of Hypertension. 28. e97–e97. 2 indexed citations

13.

Oparil, Suzanne, Michael Melino, James Lee, Víctor Fernández, & Reinilde Heyrman. (2010). Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clinical Therapeutics. 32(7). 1252–1269. 119 indexed citations

14.

Chrysant, Steven G., et al.. (2009). Efficacy and Safety of Long‐Term Treatment With the Combination of Amlodipine Besylate and Olmesartan Medoxomil in Patients With Hypertension. Journal of Clinical Hypertension. 11(9). 475–482. 52 indexed citations

15.

Rohatagi, Shashank, James Lee, Magdy Shenouda, et al.. (2008). Pharmacokinetics of Amlodipine and Olmesartan After Administration of Amlodipine Besylate and Olmesartan Medoxomil in Separate Dosage Forms and as a Fixed‐Dose Combination. The Journal of Clinical Pharmacology. 48(11). 1309–1322. 28 indexed citations

16.

Chrysant, Steven G., et al.. (2008). The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clinical Therapeutics. 30(4). 587–604. 217 indexed citations

17.

Schelfhout, Vanessa, Renaud Louis, Werner Lenz, et al.. (2005). The triple neurokinin-receptor antagonist CS-003 inhibits neurokinin A-induced bronchoconstriction in patients with asthma. Pulmonary Pharmacology & Therapeutics. 19(6). 413–418. 28 indexed citations

18.

Vanderschueren, Dirk, Reinilde Heyrman, E.J. Keogh, et al.. (1995). A Study in Patients with Erectile Dysfunction Comparing Different Formulations of Prostaglandin E1. The Journal of Urology. 154(5). 1744–1747. 8 indexed citations

19.

Backer, Wilfried A. De, et al.. (1987). Ventilation and Breathing Patterns during Hemodialysis-Induced Carbon Dioxide Unloading. American Review of Respiratory Disease. 136(2). 406–410. 17 indexed citations

20.

Broe, Marc E. De, et al.. (1986). Biocompatibility of a Polycarbonate Membrane. Blood Purification. 4(1-3). 168–171. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact